最新ニュース CareDx (NASDAQ:CDNA) 株価情報

CareDx

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

CareDx Inc

CANADIAN TIRE LTD A by Canadian Tire Corp. Ltd.

Canadian Tire Corp Ltd

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) has been analyzed by 3 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.33, a high estimate of $35.00, and a low estimate of $24.00. A 9.58% drop is evident in the current average compared to the previous average price target of $31.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1736942410_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of CareDx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CareDx's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into CareDx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About CareDx</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining CareDx's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.35% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: CareDx's net margin is impressive, surpassing industry averages. With a net margin of -8.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CareDx's ROE excels beyond industry benchmarks, reaching -2.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CareDx's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CDNA

Breaking Down CareDx: 3 Analysts Share Their Views

Wells Fargo analyst Brandon Couillard upgrades CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) from Underweight to Equal-Weight and lowers the price target from $28 to $24.

News

Upgrades

Price Target

Wells Fargo Upgrades CareDx to Equal-Weight, Lowers Price Target to $24

HC Wainwright &amp; Co. analyst Yi Chen reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral and maintains $26 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $26 Price Target

On Monday, Cathie Wood-led Ark Invest made significant trades in five major companies: Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The PLTR Trade
Ark Invest&#8217;s Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 140,518 shares of Palantir. This move is significant, considering Ark Invest&#8217;s&nbsp;<a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">recent trend of offloading Palantir shares</a>.
The total value of this trade, based on the latest closing price of $64.98, is approximately $9.1 million.
This sale follows Ark&#8217;s disposal of shares worth roughly $15 million the previous week.
Palantir stock price has fallen more than 14% over the past month. In just the first two weeks of 2025, the stock has declined nearly 15%.
The TEM Trade
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds made substantial purchases of Tempus AI Inc. shares. The ARKG fund bought 98,691 shares, while the ARKK fund purchased a whopping 280,192 shares.
Given the latest closing price of $32.34, the total value of these trades amounts to approximately $12.2 million.
This move comes amid TEM&#8217;s 13.81% drop on Monday.
Other Key Trades:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>ETF</td>
<td>Transaction</td>
<td>No. Of Shares</td>
<td>Closing price</td>
<td>Approx. Value</td>
</tr>
<tr>
<td>Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>37,358</td>
<td>$42.78</td>
<td>$1.6 million</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>65,550</td>
<td>$25.07</td>
<td>$1.6 million</td>
</tr>
</tbody>
</table>
</figure>
Closing price as of Jan. 13, 2025
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-post-joe-rogan-appearance">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Image via Benzinga YouTube and Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>

Equities

Markets

Tech

ETFs

ADPT

ARKG

ARKK

PLTR

VCYT

Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025

CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) – The Transplant Company&#x2122; – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Preliminary Fourth Quarter 2024 Financial Results
<ul>
<li>Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year.</li>
<li>Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-year.</li>
<li>Testing Services volume of approximately 45,500 increased 14% year-over-year.</li>
<li>Revenue is expected to be $11.4 million for Digital Solutions and $11.4 million for Products.</li>
<li>GAAP loss is expected to be approximately $32 million to $34 million and adjusted EBITDA is expected to be a gain of between $8 million and $9 million.</li>
</ul>
Preliminary Full Year 2024 Financial Results
<ul>
<li>2024 revenue is expected to be between $332 million to $333 million.</li>
<li>2024 GAAP loss is expected to be between $58 million and $60 million and adjusted EBITDA is expected to be a gain of between $25 million to $26 million.</li>
<li>Cash, cash equivalents, and marketable securities as of December 31, 2024, is expected to be approximately $261 million, an increase of approximately $26 million year-over-year.</li>
</ul>
2025 Revenue Guidance
<ul>
<li>CareDx anticipates revenue of $370 million during 2025.</li>
</ul>

Guidance

CareDx Expects Q4 Revenue Of $85M-$86M Vs $82.16M Est, FY24 Revenue Of $332M-$333M Vs $329.4M Est, FY25 Revenue Of $370M Vs $366.7M Est

CareDx Announced That CareDx Will Partner With TC BioPharm To Perform Pharmacokinetic Analysis Using Its AlloCell Solution In The Achieve Clinical Trial

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood&#8217;s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery. 
Speaking candidly about the sector, Wood highlighted the remarkable progress in genetic therapies, particularly in companies like Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Her most striking example involves Crispr Therapeutics&#8217; recent breakthrough in sickle cell disease treatment. Wood noted, referencing how patients who previously required 12 to 20 annual blood transfusions might now be free from such interventions.
The strategy extends beyond treatment breakthroughs to drug development itself. Wood points to companies like Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) as leveraging artificial intelligence to dramatically reduce clinical trial failure rates and accelerate drug development timelines.
However, the market performance of these innovative companies tells a more nuanced story. Year-to-date, the stocks have experienced significant volatility: Crispr Therapeutics is down 25.36%, Intellia Therapeutics has dropped 52.21%, Beam Therapeutics declined 3.04%, and Recursion Pharmaceuticals fell 9.80%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space. Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42205763/disney-reaches-43m-settlement-in-gender-pay-discrimination-lawsuit-women-can-expect-equitable-treatment-moving-forward">Disney Reaches $43M Settlement In Gender Pay Discrimination Lawsuit: &#8216;Women Can Expect Equitable Treatment&#8217; Moving Forward</a>
Why It Matters: ARK&#8217;s commitment to this sector is evident through its Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>), which manages net assets of $1.179 billion. The fund&#8217;s performance reflects the sector&#8217;s volatility, with annual returns ranging from a high of 180.50% in 2020 to a low of -53.94% in 2022.
The ETF&#8217;s current top holdings underscore Wood&#8217;s strategic focus on innovative biological technologies. Twist Bioscience Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) leads the portfolio at 8.90%, followed by Crispr Therapeutics at 7.88% and Recursion Pharmaceuticals at 6.17%. Other significant investments include CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), and Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), representing a diversified approach to genomic and biological innovation.
Wood&#8217;s vision suggests a potential $400 billion market opportunity in biologics over the next five years, driven by the unprecedented convergence of AI, sequencing technologies, and gene editing. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a></li>
</ul>
Image via Ark Invest
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Biotech

Health Care

BEAM

CRSP

NTLA

RXRX

TWST

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

BTIG analyst Sung Ji Nam maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and lowers the price target from $40 to $35.

BTIG Maintains Buy on CareDx, Lowers Price Target to $35

CareDx now expects full year 2024 non-GAAP gross margin to be approximately 69%, compared to the prior range of 67% to 68%.&nbsp;
CareDx now expects full year 2024 adjusted EBITDA gain to be in the range of $18 million to $22 million, compared to the prior guidance of an adjusted EBITDA gain of $9 million to $15 million.

CareDx Raises FY24 Revenue Guidance From $320M - $328M To $327M - $331M, Est $325.969M

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.01 by 1300 percent. This is a 177.78 percent increase over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $82.88 million which beat the analyst consensus estimate of $80.53 million by 2.93 percent. This is a 23.35 percent increase over sales of $67.19 million the same period last year.

Earnings

Earnings Beats

CareDx Q3 2024 Adj EPS $0.14 Beats $0.01 Estimate, Sales $82.88M Beat $80.53M Estimate

Ark Funds, led by Cathie Wood, is one of the most well-known fund managers thanks to its actively managed ETFs that focus on future growth <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">areas of innovation.</a>
Two of the fund's ETFs celebrate their 10th anniversaries on Thursday. Here's a look back at the funds' launch and how they've performed over the last 10 years.
Ark Innovation: Wood and<a href="https://www.benzinga.com/topic/ark-funds"> Ark Funds launched</a> the Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) on Oct. 31, 2014. The fund has grown to become the most well-known and largest of the company's funds, with $5.78 billion in assets under management.
"ARRK is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies that are relevant to the Fund's investment theme of disruptive innovation," the company's <a href="https://www.ark-funds.com/funds/arkk">website </a>says.
Disruptive innovation themes include autonomous mobility, precision therapies, next gen cloud, neural networks, intelligent devices, digital wallets, digital assets, smart contracts and multiomic technologies, according to the company.
"ARK defines ‘disruptive innovation' as the introduction of a technologically enabled new product or service that potentially challenges the way the world works."
Here are the current top 10 holdings in the ARKK ETF and their percent of net assets:
<ol>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>Shopify Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
Since the fund's inception, the ETF is up 161.4%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500.
Here's a look at how the returns of ARKK stack up against SPY, which is the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-etf-hits-milestone-as-all-time-highs-conti">oldest and largest </a>U.S. ETF, over time:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>+19.9%</td>
<td>+36.2% </td>
</tr>
<tr>
<td>3-Year</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5-Year</td>
<td>+2.6% </td>
<td>+15.8%</td>
</tr>
<tr>
<td>Since ARKK Inception 10/31/14</td>
<td>+10.2%</td>
<td>+13.2% </td>
</tr>
</tbody>
</table>
</figure>
The chart below from <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro </a>shows the 10-year return of ARKK.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1003" height="513" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" alt="" class="wp-image-624517" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" sizes="(max-width: 1003px) 100vw, 1003px" /></a></figure>
For comparison, here is the 10-year chart of the SPY. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" alt="" class="wp-image-624522" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Read Next: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">EXCLUSIVE: Cathie Wood Tells Benzinga Why Tesla Should Trade As A Tech Stock</a>
ARK Genomic: The Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) was also launched by Ark Funds on Oct. 31, 2014. The fund currently has $1.33 billion in assets under management.
"ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy, and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution," the company's <a href="https://www.ark-funds.com/funds/arkg">website </a>says.
Themes for the genomics ETF include precision therapies, multiomic technologies, programmable biology, neural networks, next gen cloud and adaptive robotics, according to the company.
Here are the current top 10 holdings in the ARKG ETF and their percent of net assets:
<ol>
<li>Twist Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>CRISPR Therapeutics: 7.0%</li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
Since the fund's inception, the ETF is up 38.9%. This return trails the current 10-year return of the SPDR S&amp;P 500 ETF Trust.
Here's a look at how the returns of ARKG stack up against SPY over time. &nbsp;
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Average Annual Returns</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1-Year</td>
<td>-7.9% </td>
<td>+36.2%</td>
</tr>
<tr>
<td>3-Year</td>
<td>-29.9%</td>
<td>+11.8% </td>
</tr>
<tr>
<td>5-Year</td>
<td>-1.9% </td>
<td>+15.8% </td>
</tr>
<tr>
<td>Since ARKG inception 10/31/14</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
Here is the 10-year chart of ARKG. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="510" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" alt="" class="wp-image-624525" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Why It's Important: The charts above show that ARKK and ARKG both experiences several years of strong growth and returns for investors, but have underperformed the broader S&amp;P 500 market index in recent years.
The ETFs were once among the most talked about funds, and the company&#8217;s daily trading activity often moved stocks higher, given Wood's outperformance years ago.
While the S&amp;P 500 ETF rebalances quarterly, the actively managed funds complete trades almost every day. Often, the average cost of shares rises over time for stocks that are going up, potentially hurting the gains.
Ark Funds typically invests in companies that it believes will have strong growth over the next five to ten years, which means the funds&#8217; returns can sometimes take years to pay off.
Wood has been early to many themes, including buying shares of NVIDIA Corporation for around $5 in 2014, before the most recent stock split. The fund later sold out of its position in late 2022 and early 2023 and<a href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early"> missed out on huge gains </a>over the last nearly two years.
The fund manager was also early in the Tesla growth story, <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">predicting a $4,000 price target</a> for the electric vehicle company back in February 2018. While Wood was laughed at for the price prediction at the time, the stock would hit the target on a split-adjusted basis in January 2021.
Getting the Tesla prediction right helped elevate Wood's status as a fund manager and led to increased interest in the Ark Funds ETFs.
Although interest in Ark Funds ETFs may have cooled in recent years, many investors still recall their impact and continue to track daily trading activity, watching closely which stocks Wood selects to hold for the next five to 10 years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">EXCLUSIVE: Why Does Cathie Wood Think Bitcoin Is Going To $1 Million — What Does She Know That We Don&#8217;t?</a></li>
</ul>
Image courtesy of Ark Invest and Shutterstock.

Broad U.S. Equity ETFs

Education

Specialty ETFs

COIN

HOOD

IONS

NRIX

NTRA

PATH

RBLX

ROKU

SHOP

TSLA

VYCT

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

CareDx, Dovetail Genomics Enter Strategic Partnership To Drive Next Wave Of Innovation In HLA Genotyping For Organ And Stem Cell Transplant Matching

In the preceding three months, 5 analysts have released ratings for CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CareDx and provided 12-month price targets. The average target is $32.2, accompanied by a high estimate of $40.00 and a low estimate of $26.00. This upward trend is apparent, with the current average reflecting a 50.96% increase from the previous average price target of $21.33.
<img src="https://www.benzinga.com/files/images/story/2024/1729602140_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CareDx. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of CareDx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About CareDx</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, CareDx showcased positive performance, achieving a revenue growth rate of 31.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CareDx's net margin excels beyond industry benchmarks, reaching -1.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CareDx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.12.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 5 Analyst Recommendations For CareDx

HC Wainwright &amp; Co. analyst Yi Chen reiterates CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Neutral.

HC Wainwright & Co. Reiterates Neutral on CareDx

Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for CareDx, revealing an average target of $32.2, a high estimate of $40.00, and a low estimate of $26.00. Marking an increase of 50.96%, the current average surpasses the previous average price target of $21.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1729090812_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of CareDx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into CareDx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know CareDx Better</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>Breaking Down CareDx's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining CareDx's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 31.26% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.51%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CareDx's ROE excels beyond industry benchmarks, reaching -0.54%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CareDx's ROA excels beyond industry benchmarks, reaching -0.3%. This signifies efficient management of assets and strong financial health.
Debt Management: CareDx's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess CareDx: What You Need To Know

Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) with a Buy and raises the price target from $26 to $35.

Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $35

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.
The Dow traded down 0.30% to 42,937.44 while the NASDAQ fell 0.84% to 18,347.17. The S&amp;P 500 also fell, dropping, 0.43% to 5,834.67.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares jumped by 2% on Tuesday.
In trading on Tuesday, energy shares fell by 2.3%.
Top Headline
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported upbeat results for its third quarter.
The company posted adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of $22.47 billion, up 5.2% year over year and beating the consensus of $22.16 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares shot up 21% to $13.78 after the company announced it signed a signed a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under the CHIPS and Science Act.</li>
<li>Shares of MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) got a boost, surging 14% to $5.28 after safety and tolerability was confirmed in its gene therapy study for Parkinson&#8217;s.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares were also up, gaining 13% to $8.56 following a third-quarter earnings beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 43% to $1.4050. Seelos Therapeutics announced notice of delisting from Nasdaq and transfer of listing to Over-the-Counter Market.</li>
<li>Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) were down 14% to $26.85 as the company reported preliminary results for the third quarter.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) was down, falling 14% to $0.1070 after the company announced a 1-for-50 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded down 4.5% to $70.54 while gold traded up 0.4% at $2,676.80.
Silver traded up 1.2% to $31.69 on Tuesday, while copper fell 1.6% to $4.3360.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 slipped 0.80%, Germany's DAX slipped 0.11% and France's CAC 40 fell 1.05%. Spain's IBEX 35 Index rose 0.67%, while London's FTSE 100 fell 0.52%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index falling 3.67%, China's Shanghai Composite Index dipping 2.53% and India's BSE Sensex falling 0.19%.
Economics
The NY Empire State Manufacturing Index declined to -11.9 in October from 11.5 in the previous month and topping market estimates of 3.8.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Trading Ideas

ERIC

MGTX

PEGY

SEEL

WOLF

Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 89.0% to $1.43 during Tuesday's regular session. The company's market cap stands at $14.4 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares moved upwards by 29.25% to $0.07. The company's market cap stands at $8.2 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares moved upwards by 20.69% to $8.34. The market value of their outstanding shares is at $49.1 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) shares increased by 20.43% to $2.41. The company's market cap stands at $71.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock moved upwards by 19.81% to $5.26. The market value of their outstanding shares is at $64.2 million. </li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) stock moved upwards by 18.36% to $3.03. The market value of their outstanding shares is at $16.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares declined by 45.3% to $1.34 during Tuesday's regular session. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 15.93% to $0.27. The company's market cap stands at $5.8 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock decreased by 15.26% to $2.69. The company's market cap stands at $78.9 million. </li>
<li>CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) shares decreased by 15.08% to $26.59. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 14.73% to $2.2. The market value of their outstanding shares is at $4.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares decreased by 14.69% to $3.83. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APRE

DWTX

GRTS

IMRX

MYNZ

NIVF

RANI

RBOT

XCUR

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday.
The Dow traded down 0.40% to 42,894.69 while the NASDAQ fell 0.93% to 18,331.05. The S&amp;P 500 also fell, dropping, 0.44% to 5,833.93.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41331971/how-to-earn-500-a-month-from-morgan-stanley-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Real estate shares jumped by 1.5% on Tuesday.
In trading on Tuesday, energy shares fell by 2%.
Top Headline
Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported revenue of $12.70 billion for the third quarter, beating the consensus of $11.87 billion.
Sales increased 7% Y/Y, reflecting higher net revenues in Global Banking &amp; Markets and Asset &amp; Wealth Management, partially offset by lower net revenues in Platform Solutions. The U.S. financial services giant reported EPS of $8.40, beating the consensus of $7.03.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares shot up 27% to $14.41 after the company announced it signed a signed a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under the CHIPS and Science Act.</li>
<li>Shares of MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) got a boost, surging 13% to $5.24 after safety and tolerability was confirmed in its gene therapy study for Parkinson&#8217;s.</li>
<li>Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) shares were also up, gaining 11% to $8.35 following a third-quarter earnings beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 52% to $1.1663. Seelos Therapeutics announced notice of delisting from Nasdaq and transfer of listing to Over-the-Counter Market.</li>
<li>Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) were down 17% to $25.93 as the company reported preliminary results for the third quarter.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) was down, falling 18% to $0.1028 after the company announced a 1-for-50 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded down 4.9% to $70.19 while gold traded up 0.4% at $2,676.10.
Silver traded up 1.2% to $31.700 on Tuesday, while copper fell 1.4% to $4.3425.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 slipped 0.40%, Germany's DAX slipped 0.01% and France's CAC 40 fell 1.10%. Spain's IBEX 35 Index rose 0.64%, while London's FTSE 100 fell 0.37%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index falling 3.67%, China's Shanghai Composite Index dipping 2.53% and India's BSE Sensex falling 0.19%.
Economics
The NY Empire State Manufacturing Index declined to -11.9 in October from 11.5 in the previous month and topping market estimates of 3.8.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41328029/top-3-tech-and-telecom-stocks-that-could-lead-to-your-biggest-gains-this-quarter">Top 3 Tech And Telecom Stocks That Could Lead To Your Biggest Gains This Quarter</a></li>
</ul>

Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday.
Shares of CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell sharply in today's pre-market trading as the company <a href="https://www.benzinga.com/quote/CDNA/news">reported preliminary results for the third quarter.</a>
CareDx said it expects third-quarter revenue of $82 million to $83 million, up approximately 23% year over year.
CareDx shares dipped 9% to $28.50 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Qurate Retail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEB#NASDAQ">QRTEB</a>) shares dipped 47.7% to $2.14 in pre-market trading. Qurate Retail will host a conference call to discuss results for the third quarter on Thursday, Nov. 7.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) shares fell 9.7% to $2.04 in pre-market trading after declining around 7% on Monday.</li>
<li>Landsea Homes Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) shares declined 7.4% to $10.50 in pre-market trading.</li>
<li>Himalaya Shipping Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSHP#NYSE">HSHP</a>) shares fell 6.2% to $7.42 in pre-market trading.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) shares fell 6.2% to $2.90 in pre-market trading.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) shares fell 6.1% to $7.05 in pre-market trading.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) shares fell 6% to $41.52 in pre-market trading. Shares of US-listed Chinese stocks traded lower after China&#8217;s September exports missed estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41327296/jim-cramer-is-worried-about-this-plane-maker-says-palo-alto-is-a-good-one">Jim Cramer Is Worried About This Plane Maker, Says Palo Alto Is A &#8216;Good&#8217; One</a></li>
</ul>

Pre-Market Outlook

HSHP

JFIN

LSEA

ORGO

QRTEB

CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

CareDx: Too Risky For Me

Natera: Poised For A Great Future But I'd Wait For A Pullback

CareDx ( ($CDNA) ) just unveiled an announcement. CareDx, Inc. announced amendments to its outside director compensation policy, which include chan...

CareDx Updates Director Compensation and Vesting Policies

CareDx guides Q4 revenue above estimates

Consensus $328.42M. Raises FY24 adjusted EBITDA view to $25M-$26M from $18M-$22M. Published first on TheFly – the ultimate source for real-time, ma...

CareDx raises FY24 revenue view to $332M-$333M from $327M-$331M

"Continuing our mission to serve transplant patients, we achieved our sixth consecutive quarter of testing services volume growth in the fourth qua...

CareDx sees FY25 revenue $370M, consensus $363.04M

Wells Fargo upgraded CareDx (CDNA) to Equal Weight from Underweight with a price target of $24, down from $28. Published first on TheFly – the ulti...

CareDx upgraded to Equal Weight from Underweight at Wells Fargo

As previously reported, Wells Fargo analyst Brandon Couillard upgraded CareDx (CDNA) to Equal Weight from Underweight with a price target of $24, d...

Wells Fargo upgrades CareDx to Equal Weight on improved risk/reward

Wells Fargo upgrades CareDx, but lowers price target

Next Century Growth Investors Q4 2024 Commentary

ADBE

ALHC

AMZN

APPF

ATRO

AVAV

AVPT

AXON

BWIN

CAVA

CBLL

DXCM

GDYN

GWRE

INOD

KIDS

KRUS

LNTH

MNDY

MPTI

MPWR

MYRG

NSSC

NVDA

ODFL

PCTY

PEGA

PNFP

PYCR

RXST

SAIA

SARO

SIBN

SPSC

TMDX

TNDM

TOST

USAP

VERX

VRRM

VRTX

WDAY

WEAV

WING

XMTR

Press Releases

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

CareDx Reports Preliminary Financial Results for Third Quarter 2024

CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting

CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

CareDx to Participate in Upcoming Investor Conferences

Contracts

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

Comments

CareDx

ニュース

最新ニュース CareDx (NASDAQ:CDNA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル